Consolidation Therapy with Idarubicin, Cisplatin and Prednisone (CIP) After P-VABEC Regimen in the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma of the Elderly

References

• O'Reilly S. E., Klimo P., Connors J. M. Low dose ACOP‐B and VABE: weekly chemotherapy for elderly patients with advanced‐stage diffuse large‐cell lymphoma. J. Clin. Oncol. 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Hoskins P., Howdle S., et al. POCE chemotherapy: phase I1 trial in elderly patients with advanced‐stage diffuse large cell lymphoma. Proc. Am. Soc. Clin. Oncol. 1992; 11: A 1116
   Google Scholar
• Orlandi E., Lazzarino M., Brusamolino E., Castelli G., Pagnucco G., Morra E., Bernasconi C. Non Hodgkin's lymphoma in the elderly: The impact of advanced age on therapeutic options and clinical results. Haematologica 1991; 76: 204–208
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Michiels J. J. Full dose chemotherapy in elderly patients with non‐Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Brit. J. Cancer 1990; 62: 105–108
   PubMed Web of Science ®Google Scholar
• Tigaud J., Demolombe S., Bastion Y., Bryon P., Coiffier B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematol. Oncol. 1991; 9: 225–233
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino D., et al. Non‐Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Study Group. J. Clin. Oncol. 1988; 6: 1708–1713
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Enante D., et al. Prospective study of a new cornhination chemotherapy regimen in patients older than 70 years with unfavorable non‐Hodgkin's lymphoma. J. Clin. Oncol. 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Bendandi M., Gherlinzoni F., Mazza P., Salvucci M., Aitini E., Miggiano M. C., Gozzetti A., Tura S. Huematologica 1993; 78: 378–382
   PubMed Web of Science ®Google Scholar
• Bessel E. M., Coutts A., Fletcher J., Toghill P. J., Moloney A. J., Ellis I. O., Hulman G., Jenkins D. Non Hodgkin's lymphoma in elderly patients: a phase 11 study of MCOP chemotherapy in patients aged 70 years or over with intermediate‐or high‐grade histology. Europ. J. Cancer 1994; 9: 1337–1341
   Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E. Effect of age on the therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J. Clin. Oncol. 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenhurger D. D. The importance of age in survival of patients treated with chemotherapy for aggressive non‐Hodgkin's lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Martelli M., Guglielmi C., Coluzzi S., Avvisati G., Amadori S., Govannini M., Torromeo C., Mandelli F. A prospective study of a new weekly chemotherapic regimen for elderly aggressive non‐Hodgkin's lymphoma. J. Clin. Oncol. 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• Caracciolo F., Petrini M., Capochiani E., Papineschi F., Grassi B. Third generation chemotherapy with P‐VABEC for aggressive Non‐Hodgkin's Lymphomas of the elderly. Leuk. Lymph. 1993; 11: 115–118
   PubMed Web of Science ®Google Scholar
• Caracciolo F., Petrini M., Capochiani E., Papineschi F., Carulli G., Grassi B. Alternating chemotherapy regimen (P‐VABEC) for intermediate and high grade non‐Hodgkin's lymphoma of the middle aged and elderly. Hematol. Oncol. 1994; 12: 185–192
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug‐resistant leukemia cells. Blood 1992; 79: 3267–3273
   PubMed Web of Science ®Google Scholar
• Petrini M., Mattii L., Valentini P., Sabbatini A. R. M., Grassi B., Grandi M. Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines. Ann. Hemathol. 1993; 67: 227–230
   PubMed Web of Science ®Google Scholar
• Testi R., Mattii L., Di Shone D., Zaccaro L., Malvaldi G., Grassi B., Petrini M. Evaluation of resistance index of several anticancer agents on parenthal and resistant P388 cell lines. Leukemia Res. 1995; 19: 257–261
   PubMed Web of Science ®Google Scholar
• Non Hodgkin's Lymphoma Classification Project. National Cancer Institute sponsored study of classifications of Non Hodgkin's Lymphoma: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Hryniuk W. Average relative dose intensity and the impact on design of clinical trials. Semin. Oncol. 1987; 14: 65–74
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., De Vita V. T., Jr., Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: a comparison of published methods. J. Clin. Oncol. 1991; 9: 2042–2051
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non parametric estimation from incomplete observations. J. Am Stat. Assoc. 1958; 53: 157
   Web of Science ®Google Scholar
• World Health Organization. Handbook for reporting results of cancer treatment. WHO. offset Publ. 48, WHO, Geneva 1979
   Google Scholar
• Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J. Am. Geriatr. Soc. 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Hande K., Channel G., Garrow G. Frequency of tumour lysis syndrome following treatment of aggressive lymphomas. Proc. ASCO 1990, Abs 1039
   Google Scholar
• Kwack L. W., Halpern J., Olshen R. A., Horning S. J. Prognostic significance of actual dose intensity in diffuse large cell‐lymphoma: result of a tree‐structurated survival analysis. J. Clin. Oncol. 1990; 8: 963–977
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Hryniuk W. M., Goodyear M. D. E. The role of dose intensity in determining outcome in intermediate‐grade non‐Hodgkin's lymphoma. J. Clin. Oncol. 1991; 9: 339–347
   PubMed Web of Science ®Google Scholar
• Silingardi V., Federico M., Cavanna L., Avanzini P., Gobbi P. G., Lombardo M., Carotenuto M., Frassoldati A., Pieresca C., Vallisa D., Merli F., Ascari E., Mauri C. ProMECE‐CytaBOM vs MACOP‐B in advanced aggressive non‐Hodgkin's lymphoma: long term result of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk. Lymph. 1995; 17: 313–320
   PubMed Web of Science ®Google Scholar